Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

SpringerPlus

Table 3 Annual drug costs for breast cancer adjuvant endocrine agents under medicare Part D and after availability of generic alternatives

	2006 annual costs ^a	2010 annual costs ^a	2006 to 2010	2011 annual costs ^a,b	2006 to 2011	2010 to 2011
Drug	Median of state mean costs	Median of state mean costs	Change in median cost (%)	Median of state mean costs	Change in median cost (%)	Change in median cost (%)
	Median of state mean costs	Median of state mean costs		$, (Range of mean costs)
	$, (Range of mean costs)	$, (Range of mean costs)		$, (Range of mean costs)
Arimidex/Anastrozole	1432.96 (1345.26-1547.73)	3050.37 (2943.92-3365.10)	+113	872.20 (731.51-994.31)	−39	−71
Aromasin/Exemestane	1482.73 (1401.17-1596.30)	2804.33 (2674.05-3141.44)	+89	1836.93 (1645.53-2418.20)	+24	−34
Letrozole/Femara	1598.18 (1463.09-1681.52)	3663.61 (3535.16-4006.99)	+129	2217.49 (2083.11-2375.56)	+39	−39
Tamoxifen	588.18 (520.13-648.77)	701.18 (558.66-780.02)	+19	804.03 (660.68-881.69)	+37	+15

^aRange and median of mean annual drug costs of Part D plans across 50 states and the District of Columbia. Annual drug cost values represent the aggregate cost to the patient of taking only that drug at recommended dosing for an entire year, including deductible and drug-specific costs, but not the plan premiums. These values were provided directly from the CMS website, and obtained by entering the relevant drug as the only drug to be taken for the year.
^bFirst full year in which generic aromatase inhibitor agents were made available to Medicare Part D beneficiaries; generic cost provided.